Business
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)Name change to be effective following shareholder approval, which is expected at the Extraordinary General
About this update from Everest Medicines Ltd.
[{"type":"image","alt":"I-Mab Biopharma","displaySize":"","headline":null,"caption":"I-Mab Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/61ac48be92843ad3a8f6edb37f7d267b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DTRvkLgQJmaP3Tu1mRuU.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/61ac48be92843ad3a8f6edb37f7d267b","width":300,"height":109}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"Intention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EGM) on October 24, 2025","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Pending acquisition of AM712 (also known as ASKG712), to be named VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, and a more potent molecule that could potentially provide more effective and durable treatment benefits for patients with wet AMD and DME than current standard of care. The pending acquisition will be completed by a newly formed subsidiary Visara, Inc., a clinical-stage biopharmaceutical company focused on the development of ophthalmic therapeutics for serious eye disorders","length":504,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Mr. Kyler Lei as Chief Financial Officer, bringing significant expertise in Hong Kong and global capital markets","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1165,"olType":false},{"type":"text","content":"ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, announced its new business model, focused on it...